PT  - JOURNAL ARTICLE
AU  - Arsela Prelaj
AU  - Sara Elena Rebuzzi
AU  - Gabriella Del Bene
AU  - Julio Rodrigo Giròn Berrìos
AU  - Alessandra Emiliani
AU  - Lucilla De Filippis
AU  - Alessandra Anna Prete
AU  - Silvia Pecorari
AU  - Gaia Manna
AU  - Carla Ferrara
AU  - Daniele Rossini
AU  - Flavia Longo
TI  - Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC
AID  - 10.1183/23120541.00128-2016
DP  - 2017 Jan 01
TA  - ERJ Open Research
PG  - 00128-2016
VI  - 3
IP  - 1
4099  - http://openres.ersjournals.com/content/3/1/00128-2016.short
4100  - http://openres.ersjournals.com/content/3/1/00128-2016.full
SO  - erjor2017 Jan 01; 3
AB  - In small-cell lung cancer (SCLC), the role of chemotherapy and radiotherapy is well established. Large-cell neuroendocrine carcinoma (LCNEC) shares several clinicopathological features with SCLC, but its optimal therapy is not defined. We evaluated clinical response and survival outcomes of advanced LCNEC treated in first-line therapy compared with SCLC.72 patients with stage III–IV LCNEC (n=28) and extensive-stage SCLC (ES-SCLC) (n=44) received cisplatin–etoposide with/without thoracic radiotherapy (TRT) and prophylactic cranial irradiation (PCI).Comparing LCNEC with SCLC, we observed similar response rates (64.2% versus 59.1%), disease control rates (82.1% versus 88.6%), progression-free survival (mPFS) (7.4 versus 6.1 months) and overall survival (mOS) (10.4 versus 10.9 months). TRT and PCI in both histologies showed a benefit in mOS (34 versus 7.8 months and 34 versus 8.6 months, both p=0.0001). LCNEC patients receiving TRT showed an improvement in mPFS and mOS (12.5 versus 5 months, p=0.02 and 28.3 versus 5 months, p=0.004), similarly to ES-SCLC. PCI in LCNEC showed an increase in mPFS (20.5 versus 6.4 months, p=0.09) and mOS (33.4 versus 8.6 months, p=0.05), as in ES-SCLC.Advanced LCNEC treated with SCLC first-line therapy has a similar clinical response and survival outcomes to ES-SCLC.Cisplatin–etoposide is an efficient treatment for large-cell neuroendocrine carcinoma. RT and PCI improve survival. http://ow.ly/sBJo309HG8s